GlycoMimetics to Present at the Cowen and Company 40th Annual Health Care Conference 2020
February 25 2020 - 09:00AM
Business Wire
GlycoMimetics, Inc. (Nasdaq:
GLYC) today announced that Chief Executive Officer Rachel King will
provide a company overview at the Cowen and Company 40th Annual
Health Care Conference in Boston, on Tuesday, March 03, 2020, at
12:00 p.m. ET.
To access the live webcast and subsequent archived recordings
for the presentation, please visit the GlycoMimetics website at
www.glycomimetics.com.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company focused
on the discovery and development of novel glycomimetic drugs to
address unmet medical needs resulting from diseases in which
carbohydrate biology plays a key role. GlycoMimetics' wholly owned
drug candidate, uproleselan, an E-selectin antagonist, was
evaluated in a Phase 1/2 clinical trial as a potential treatment
for acute myeloid leukemia (AML). It has received Breakthrough
Therapy Designation from the U.S. Food and Drug Administration and
is being evaluated across a range of patient populations including
a company-sponsored Phase 3 trial in relapsed/refractory AML.
GlycoMimetics has also completed a Phase 1 clinical trial with
GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics
is located in Rockville, MD in the BioHealth Capital Region. Learn
more at www.glycomimetics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200225005310/en/
Investor Contact: Shari Annes Phone: 650-888-0902 Email:
sannes@annesassociates.com
Media Contact: Jamie Lacey-Moreira Phone: 410-299-3310
Email: jamielacey@presscommpr.com
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Feb 2024 to Mar 2024
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Mar 2023 to Mar 2024